

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

The Synthesis and Antiviral Activity of Some New S-Adenosyl-L-homocysteine Derivatives and Their Nucleoside Precursors

Pawel Serafinowski^a; Erwin Dorland^a; Jan Balzarini^b; Erik De Clercq^b

^a CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, U. K. ^b Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium

To cite this Article Serafinowski, Pawel , Dorland, Erwin , Balzarini, Jan and De Clercq, Erik(1995) 'The Synthesis and Antiviral Activity of Some New S-Adenosyl-L-homocysteine Derivatives and Their Nucleoside Precursors', *Nucleosides, Nucleotides and Nucleic Acids*, 14: 3, 545 – 547

To link to this Article: DOI: 10.1080/15257779508012423

URL: <http://dx.doi.org/10.1080/15257779508012423>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

THE SYNTHESIS AND ANTIVIRAL ACTIVITY OF SOME NEW S-ADENOSYL-L-HOMOCYSTEINE DERIVATIVES AND THEIR NUCLEOSIDE PRECURSORS

Pawel Serafinowski, Erwin Dorland, Jan Balzarini^a and Erik De Clercq^a

CRC Centre for Cancer Therapeutics, Institute of Cancer Research,
15 Cotswold Road, Sutton, Surrey, SM2 5NG, U.K.

^aRega Institute for Medical Research, Katholieke Universiteit Leuven,
Minderbroedersstraat 10, B-3000 Leuven, Belgium


S-Adenosyl-L-homocysteine (SAH) and some of its analogues are potent inhibitors of transmethylation reactions catalysed by S-adenosyl methionine dependent methyltransferases.¹

S-Tubercidinyl-L-homocysteine (STH) is the most potent and metabolically stable inhibitor of several methyltransferases described to date.^{2,3} In order to examine the effect of various structural modifications to the heterocyclic moiety on the compound's biological activity, S-2-methyltubercidinyl-L-homocysteine (**10a**) and S-2-chlorotubercidinyl-L-homocysteine (**10b**) were prepared.

The synthesis of compounds **10a** and **10b** is presented in the Scheme. Initially, the synthesis of the required nucleoside precursors 2-methyltubercidin (**7a**) and 2-chlorotubercidin (**7b**) was attempted via ribosylation of 4-Chloro-2-methylpyrrolo[2,3-d]pyrimidine (**4a**)⁴ and 2,4-dichloropyrrolo[2,3-d]pyrimidine (**4b**)⁵ respectively, with 2,3,5-tri-O-benzoyl- α,β -D-ribofuranosyl chloride. The reaction was carried out under the solid-liquid phase transfer conditions using acetonitrile containing powdered potassium hydroxide and tris[2-(2-methoxyethoxy)ethyl]amine (TDA-1) as a catalyst⁶. However, instead of the expected products of glycosylation **1a** and **1b**, compounds of type **2**⁷ were isolated in 60-70% yield. The same products were obtained when the heterocyclic bases were ribosylated with 1-O-acetyl-2,3,5-tri-O-benzoyl- β -D-ribofuranose in the presence of stannic chloride⁸ or trimethylsilyl iodide⁹.

Compounds **4a** and **4b** were therefore condensed with 5-O-t-butyl-dimethylsilyl-2,3-O-isopropylidene- α -D-ribofuranosyl chloride (**3**)¹⁰ under the solid liquid phase-transfer conditions similar to those applied during the condensations described above. The ribosylations showed a high preference for the required N-9 isomer and accordingly compounds **5a** and **5b** were isolated by column chromatography on silica gel in 70 and 60% yield, respectively.

The protecting groups were removed from **5a** and **5b** by the action of trifluoroacetic acid. The resulting products of deprotection **6a** and **6b** were then aminated with 8 M methanolic ammonia to afford crystalline 2-methyltubercidin (**7a**)¹¹ and 2-chlorotubercidin (**7b**).



SCHEME

The nucleosides **7a** and **7b** were subsequently condensed with N,N'-bis-trifluoroacetyl-L-homocystine dimethyl ester (**8**) in the presence of triethylphosphine.^{12,13} The N-trifluoroacetyl-S-tubercidinyl-L-homocysteine methyl esters **9a** and **9b**, obtained as a result, were isolated in 34 and 54% yield, respectively, by column chromatography on silica gel. Finally, the carboxyl and amino functions in **9a** and **9b** were deprotected with 0.25 M barium hydroxide in 50% aqueous methanol^{12,13} to give S-2-methyltubercidinyl-L-homocysteine (**10a**) in 53% yield, and S-2-chlorotubercidinyl-L-homocysteine (**10b**)¹⁴ in 63% yield, after anion exchange chromatography on Sephadex A-25.

The compounds were evaluated for their activity against several viruses such as herpes simplex, vaccinia, vesicular stomatitis, Coxsackie, polio, parainfluenza, reo, Sindbis and Semliki forest in Vero, HeLa and E₆SM cell cultures. A minimum inhibitory concentration of 20 µg/mL was noted in some cases, ie with compound **7b** against Coxsackie B4 and polio-1, but otherwise no antiviral activity was observed.

ACKNOWLEDGEMENT

This investigation was supported by the Cancer Research Campaign.

REFERENCES

1. Wolfe, M.S.; Borchardt, R.T. *J. Med. Chem.* 1991, **34**, 1521.
2. Ueland, P.M. *Pharmacol. Rev.* 1982, **34**, 223.
3. Cantoni, G.L. in *Biological Methylation and Drug Design*, Borchardt, T.R.; Cravelling, C.S.; Ueland, P.J. (eds) Humana Press, Clifton, New Jersey (1986), p.222.
4. Davoll, J. *J. Chem. Soc.* 1960, 131.
5. Saxena, N.K.; Hagenow, B.M.; Genzlinger, G.; Turk, S.R.; Brach, J.C.; Townsend, L.B. *J. Med. Chem.* 1988, **31**, 1501.
6. Seela, F.; Bourgeois, W. *Synthesis* 1989, 912
7. Lüpke, U.; Hasselmann, D.; Seela, F. *Chem. Ber.*, 1980, **113**, 2808
8. Vorbrüggen, H.; Höffle, G. *Chem. Ber.* 1981, **114**, 1256
9. Točik, Z.; Earl, R.A.; Beranek, J. *Nucleic Acids Res.* 1980, **8**, 4755
10. Wilcox, C.S.; Oloski, R.M. *Tetrahedron Lett.* 1986, **27**, 1011
11. Kazimierczuk, Z.; Revankar, G.R.; Robins, R.K. *Nucleic Acids Res.* 1984, **12**, 1179.
12. Serafinowski, P. *Nucleic Acids Res.* 1987, **15**, 1121.
13. Serafinowski P.; Dorland, E.; Harrap, K.R.; Balzarini, J.; De Clercq, E. *J. Med. Chem.* 1992, **35**, 4576
14. All the compounds were fully characterised by their analytical and spectroscopic data.